Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

Journal article

Cappuccini F. et al, (2020), Journal for ImmunoTherapy of Cancer, 8, e000928 - e000928

Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice.

Journal article

Bliss CM. et al, (2020), Molecular therapy. Methods & clinical development, 16, 108 - 125

VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer.

Conference paper

Redchenko I. et al, (2018), Journal of Clinical Oncology, 36, 3018 - 3018

5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy

Journal article

Cappuccini F. et al, (2017), Oncotarget, 8, 47474 - 47489

Extracellular Adenosine Production by ecto-5′-Nucleotidase (CD73) Enhances Radiation-Induced Lung Fibrosis

Journal article

Wirsdörfer F. et al, (2016), Cancer Research, 76, 3045 - 3056